Table 1.
Summary of included studies.
| Authors | Drug | Cancer Diagnosis | Neuropathy Measure | Percentage of Sample with Neuropathy |
|---|---|---|---|---|
| Grim et al. [12] | Paclitaxel | Breast | Michigan Neuropathy Screening Instrument | 60% 1 |
| Jennaro et al. [10] | Paclitaxel | Breast | EORTC CIPN-20 5 | 32.4% |
| Ottaiano et al. [13] | Oxaliplatin | Colorectal | CTCAE 6 | 17.7% |
| Robertson et al. [11] | Paclitaxel | Breast | TNS 7 | 42% |
| Saito et al. [17] | Vincristine | Lymphoma | CTCAE | 17.5% 2 |
| Shahriari-Ahmadi et al. [14] | Oxaliplatin | Colorectal | CTCAE | 80.7% |
| Velasco et al. [20] | Platinum or taxane | Colorectal, gastric, lung, or breast | TNS CTCAE Nerve conduction studies |
52% 4 |
| Vincenzi et al. [15] | Oxaliplatin | Colorectal | CTCAE | 40% |
| Wang et al. [18] | Thalidomide/velcade | Multiple myeloma | CTCAE FACT/GOG-NTX 8 |
59% |
| Winkels et al. [16] | Oxaliplatin/ capecitabine |
Colorectal | CIPN20 | 81% |
| Yildirim et al. [19] | Oxaliplatin | Gastrointestinal (colorectal, gastric, or pancreatic) | CTCAE | 42% 2,3 |
1 Listed as CIPN complications; 2 grade 2–3 CIPN; 3 58% had grade 0–1 CIPN; 4 the overall percentage of people who developed neuropathy (grade > 0) was higher at 88% for those receiving platinum and 79% for those receiving paclitaxel; 5 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale; 6 Common Terminology Criteria for Adverse Events; 7 Total Neuropathy Score; 8 Functional Assessment of Cancer Therapy Scale/Gynecologic Oncology Group-Neurotoxicity.